Santa Cruz Biotechnology Opens New Office in Canada

The new location will provide better support for Canadian customers

Mississauga, Ontario (PRWEB) October 27, 2016

Santa Cruz Biotechnology, Inc., a world leader in the development of products for the biomedical research market, announces expansion to a new sales office opening near Toronto, Canada to accommodate their rapid growth and future expansion plans. The 20,000 square foot facility located in Mississauga, Canada, will provide capacity for continued growth and meet demands for new monoclonal antibodies and research products. Mississauga boasts a population rich in diversity, culture and history. Now being Canada's 6th largest city, Mississauga is an important hub for industry and commerce, and serves as headquarters to 60 of the world's Fortune 500 companies.

Founders John and Brenda Stephenson are excited about the expansion into Canada. "Santa Cruz Biotechnology, Inc.'s new office space will allow us to increase capabilities that align with our current and future growth plans. The new space will allow us to to cater to sales and to support the growth we are experiencing. This move represents a commitment to continue building on the success our team has accomplished." said Dr. John Stephenson. Dr. Stephenson, a Canadian native born in Vancouver, British Columbia, sees it as a ‘homecoming'. He received his Ph.D in Biological Sciences from the University of Toronto.

About Santa Cruz Biotechnology, Inc.

Santa Cruz Biotechnology is the leading producer of monoclonal antibodies, RNAi, CRISPR KO/Activation products, biochemicals and labware for research use. Over the past twenty five years, the company has focused on the ongoing development of these products. Santa Cruz Biotechnology upholds the highest commitment to quality and customer service. The company is headquartered in Dallas, Texas, and has offices in California, Idaho, Germany, China, and now Canada.

For more information, contact Santa Cruz Biotechnology, Inc. at http://www.scbt.com

For the original version on PRWeb visit: http://www.prweb.com/releases/2016/10/prweb13797120.htm